New prognostic and predictive factors in breast cancer

Minerva Ginecologica

Volumn 62, Issue 6, 2010, Pages 599-611

  Schmidt, M ^a   Gehrmann, M ^b,c   Hengstler, J G ^d   Koelbl, H ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Siemens Healthcare Diagnostic Products   (Germany)

^c BAYER AG   (Germany)

^d TU DORTMUND UNIVERSITY   (Germany)

Author keywords

Breast neoplasms; Gene expression; Immune system

Indexed keywords

ADECATUMUMAB; ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; IMMUNOGLOBULIN KAPPA CHAIN; ISOMERASE; KI 67 ANTIGEN; LETROZOLE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TOPOISOMERASE II ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG; UROKINASE;

BREAST CANCER; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; METASTASIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PREDICTION; PREDICTIVE VALUE; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE;

BREAST NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; GENETIC MARKERS; HUMANS; MOLECULAR TARGETED THERAPY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SERINE PROTEINASE INHIBITORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 79952241049     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822.
2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92. (Pubitemid 41549890)
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
4. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn H. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-29.
5. Fisher ER, Costantino J, Fisher B, Redmond C. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators Cancer 1993;71:2141-50. (Pubitemid 23070681)
6. Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004;22:1630-7. (Pubitemid 41079801)
7. Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thürlimann B, Senn H. First-select the target: better choice of adjuvant treatments for breast cancer patients Ann Oncol 2006;17:1772-6.
8. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91. (Pubitemid 32176272)
9. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005,23:2716-25. (Pubitemid 46179461)
10. Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 2009;10:1070-6.
11. Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J. Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol 2009;27:214-9.
12. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006,98:1183-92. (Pubitemid 44390989)
13. Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, Lebrecht A et al. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer - comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol 2009;20:258-64.
14. Jung S, Han W, Lee JW, Ko E, Kim E, Yu J et al. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol 2009;16:1112-21.
15. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008;100:207-12. (Pubitemid 351480546)
16. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-20.
17. Petit T, Wilt M, Veiten M, Millon R, Rodier J, Borel C et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004;40:205-11. (Pubitemid 38077022)
18. Chang J, Powles TJ, Allred DC, Ashley SE, Makris A, Gregory RK et al. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res 2000;6:616-21.
19. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;26:5569.
20. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
21. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
22. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
23. Schmidt M, Böhm D, Törne C von, Steiner E, Puhl A, Pilch H et al. The humoral immune system has a key prognostic impact in node-negative breast cancer Cancer Res 2008;68:5405-13.
24. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004;10:6622-8. (Pubitemid 39346559)
25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
26. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 2009;14:320-68.
27. Schmidt M, Lewark B, Kohlschmidt N, Glawatz C, Steiner E, Tanner B et al. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res 2005;7:R256-66.
28. Petry IB, Fieber E, Schmidt M, Gehrmann M, Gebhard S, Hermes M et al. ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer. Clin Cancer Res 2010;16:451-60.
29. Laurentiis M de, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741-8. (Pubitemid 41557193)
30. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-11. (Pubitemid 43736610)
31. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496-506. (Pubitemid 47572635)
32. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
33. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010;28:92-8.
34. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994;125:437-46. (Pubitemid 24135956)
35. Trzpis M, McLaughlin PMJ, Leij LMFH de, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 2007;171:386-95. (Pubitemid 47344671)
36. Gastl G, Spizzo G, Obrist P, Dünser M, Mikuz G. EpCAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356:1981-2.
37. Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, Steiner E et al. Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res 2008;14:5849-55.
38. Schmidt M, Petry IB, Böhm D, Lebrecht A, Törne C von, Gebhard S et al. Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer. Breast Cancer Res Treat 2010 [Epub ahead of print].
39. Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol 2010;21:275-82.
40. Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopathology 2008;52:108-18. (Pubitemid 350265179)
41. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
42. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
43. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. (Pubitemid 47219710)
44. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009;115:423-8.
45. Rakha EA, Tan DSP, Foulkes WD, Ellis IO, Tutt A, Nielsen TO et al. Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res 2007;9:404; author reply 405.
46. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.
47. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009;15:2302-10.
48. Bartlett JMS, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 2008;26:5027-35.
49. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV et al. Retrospective analysis of topoisomerase Ha amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23:7483-90. (Pubitemid 46291811)
50. Bartlett JMS, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 2010;11:266-74.
51. Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 2010;16:2391-401.
52. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-72.
53. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66. (Pubitemid 26340047)
54. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52.
55. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
56. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993;24:195-208. (Pubitemid 23062819)
57. Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28. (Pubitemid 34121291)
58. Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001;93:913-20. (Pubitemid 32624648)
59. Thomssen C, Harbeck N, Dittmer J, Abraha-Spaeth SR, Papendick N, Paradiso A et al. Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens. J Natl Cancer Inst 2009;101:1028-9.
60. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U.S.A. 2001;98:10869-74.
61. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JGM et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008,68:3108-14.
62. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85. (Pubitemid 41170290)
63. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
64. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.
65. van Veer LJ 't, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
66. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009. (Pubitemid 35461656)
67. Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 2010;21:717-22.
68. Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009;116:295-302.
69. Cardoso F, van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008;26:729-35.
70. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-267
71. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34. (Pubitemid 46622311)
72. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh I et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
73. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829-34.
74. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26:721-8. (Pubitemid 351264384)
75. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
76. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-46. (Pubitemid 46640570)
77. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9. (Pubitemid 44200649)
78. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2008;8:R157.
79. Calabrò A, Beissbarth T, Kuner R, Stojanov M, Benner A, Asslaber M et al. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat 2009;116:69-77.
80. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 2009;11:R15.
81. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, DeLisi C et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 2007;67:10669-76. (Pubitemid 350145892)
82. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:105-13.
83. Schmidt M, Hengstler JG, Tome C von, Koelbl H, Gehrmann MC. Coordinates in the universe of node-negative breast cancer revisited. Cancer Res 2009;69:2695-8.
84. Schmidt M, Petry IB, Boehm D, Lebrecht A, Gehrmann M, Hengstler JG et al. Immunoglobulin Kappa C has independent prognostic significance in node-negative breast cancer. Cancer Res 2009;69(Suppl.):729S.